PuriBlood Medical announced the launch of its Small Animal Business Division and a strategic partnership with Utah Medical, a U.S.-listed medical consumables manufacturer. Through this collaboration, PuriBlood has secured exclusive Taiwanese distribution rights for Utah Medical’s Hemo-Nate 18μm microfilter, with projected annual revenues reaching tens of millions of New Taiwan Dollars within five years. The move also aims to gradually enhance the blood supply ecosystem for pets.
PuriBlood’s small animal brand, PuriVet, is the world’s first to apply leukoreduction filter technology to animal transfusions and has developed blood bags specifically for dogs and cats. The brand has established recognition in the North American market and holds a leading market share in Taiwan, tapping into a pet industry with an annual market value exceeding NT$60 billion.
Beyond filters and blood bags, PuriVet is actively developing solutions in the CGM (continuous glucose monitoring) space. In collaboration with a U.S. CGM manufacturer, PuriVet has developed animal-specific products currently undergoing clinical testing, with animal trials expected to conclude by year-end and commercial orders slated to begin shortly thereafter. Additionally, PuriVet will partner with ABRI, the largest veterinary blood bank in the U.S., to develop dedicated kits and import blood-related products, further elevating the standard of pet healthcare in Taiwan.
PuriVet has long cultivated the global animal transfusion market. The newly introduced Hemo-Nate 18μm microfilter effectively removes micro-particles and aggregates from blood and infusions, preventing lung distress or excessive microvascular load in pets. The device is referenced in over 200,000 international research papers and veterinary textbooks.
According to the Ministry of Agriculture, nearly 2.8 million pets are registered in Taiwan, with numbers rising annually—far outpacing the newborn population—highlighting the rapid growth of the pet economy. PuriBlood anticipates strong growth potential in Taiwan’s pet healthcare market over the next three years, planning to begin shipments in Q4 and targeting over NT$100 million in revenue within three years, demonstrating significant expansion momentum.
PuriBlood emphasized that PuriVet will continue to drive pet healthcare innovation through advanced medical devices and international collaboration, building a more comprehensive pet care ecosystem. With the establishment of the Small Animal Business Division, the company aims to leverage a clear brand strategy and synergistic product lines to enter global markets, creating higher market value and investment returns.
Resource: 普瑞博攜手美國醫療大廠Utah Medical 升級毛寵醫療品質、擴大全球布局
